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impact of maneuvers aimed at better flushing/preserving peribiliary vascular plexus and biliary 
mucosa: addition of Epoprostenol (Ep) {Flolane}-potent vasodilator & platelet inhibitor normally 
produced by endothelial cells- in the pressurized (100 mmHg) UW preservation solution; this protocol 
was applied to all locally procured livers since 01/09/1999. Incidence of BS was 19.1% (77/403). 
Average time of diagnosis was 253 days (7 days-1002 days). In univariate analysis (Fisher exact & 
Chi X2; T-test & Mann Whitney-U test, significance set at <0.05), absence of flushing of donor bile 
ducts, import vs locally procured liver, and rejection were risk factors for BS. On the contrary, 
following factors were protective: donor cardiac arrest followed by resuscitation (suggesting an 
ischemic preconditioning effect) and Ep/pressurization. Patients with higher postTx peak of 
transaminase, bilirubine, alkaline phosphatase, and !-GT were at higher risk for later development of 
BS. Donor-hypotension, -age, and -ICU stay, type of preservation, positive cross-match, cold & warm 
ischemia times, sequential vs simultaneous portal/arterial reperfusion, and CMV infection were no risk 
factors for BS. In multivariate analysis (significance set at <0.01), only Ep-pressurization appeared to 
protect from BS. In conclusion, this study makes 2 novel points: 1. Patients with high(er) 
transaminase and cholestasis early postTx are at higher risk of developing BS later and should be 
closely monitored; 2. Donor maneuvers aimed at better flushing/preserving peribiliary vascular plexus 
and biliary mucosa (Ep-pressurization of preservation solution) protect from BS. If confirmed in a 





A RETROSPECTIVE MONOCENTRIC REVIEW OF SIMULTANEOUS PANCREAS KIDNEY 
TRANSPLANTATION.  
Decker E, Coimbra C, Weekers L, Detry O, Honoré P, Squifflet JP, Meurisse M, De Roover A. Ser-
vice de Chirurgie Abdominale et Transplantation, CHU de Liège, Belgium. 
Background: Pancreas transplantation has emerged as an effective treatment for patients with type 
1 diabetes associated with end-stage renal disease. In this paper, we review a consecutive series of 
simultaneous pancreas-kidney (SPK) transplantations performed in our institution over a 6 years pe-
riod. 
Methods: The study population included 22 patients (15 males and 7 females) who underwent SPK 
transplantation between 2001 and 2007. The mean recipient age was 47 (26-63). Eighteen patients 
suffered from type 1 and 4 from type 2 diabetes. The mean donor age was 33 (14-56). The mean of 
HLA histocompatibility matching was 2.1(1-5). Mean renal and pancreatic cold ischemia time were re-
spectively 7h42 and 8h52, Immunosuppressive treatment consisted of basiliximab induction followed 
by a triple association (tacrolimus, mycophenolate mofetil and prednisone). Mean hospital stay was 
20 days (11-52). 
Results: Among 22 recipients, patient survival rate was 86% after a mean follow-up of 44 months 
(17-88). Two patients died in the immediate post-operative period: 1from disseminated intravascular 
coagulation (DIC) and multi-systemic failure in the immediate postoperative period and 1 from pulmo-
nary embolism at home 45 days after surgery. A third patient died from pulmonary infection after 48 
months with functional grafts. Early postoperative complication associated with kidney graft was one 
case of vascular thrombosis that needed POD 1 graft withdrawal. After a second renal transplantation 
2 days later, she developed an acute rejection successfully treated by plasmapheresis and Rituximab. 
The patient with DIC suffered both from kidney and pancreas graft thrombosis. Other early complica-
tions associated with pancreas transplant included 2 cases with immediate reperfusion defects that 
led to early vascular thrombosis in one patient and duodenal graft fistula in the other patient. These 
two cases needed pancreas graft withdrawal.  For the 19 patients currently alive, kidney graft survival 
was 95% (18/19). Only one patient lost his kidney secondary to rejection due to non compliance. 
Pancreas graft survival was 84% (16/19). Graft loss was due to rejection for two patients (including 
the case of non compliance) and pancreatic fistula in one case. 
Conclusion: SPK is a valid therapeutic option for patients with insulin-dependent diabetes and renal 
failure from diabetic nephropathy. In our series, patient, kidney and pancreas graft survival were re-
spectively 86%, 82% and 73% after a mean follow-up of 44 months. Main complications of SPK trans-
plantation occur in the immediate postoperative period consecutive to vascular or rejection processes. 
